Search results

guselkumab (Tremfya)

For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or Janus kinase (JAK) inhibitor.

guselkumab (Tremfya)

For the treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.

guselkumab (Tremfya)

For the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy, alone or in combination with methotrexate (MTX).

guselkumab (Tremfya)

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

November 2025 decisions news release

June 2018 decisions news release

The Scottish Medicines Consortium (SMC), has today (Monday 11 June) published advice accepting six new medicines for use by NHSScotland. Five of the medicines were accepted through SMC’s Patient and Clinician Engagement (PACE) process.

August 2021 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 9 August) published advice accepting six new medicines.